JP2024518429A - ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態 - Google Patents

４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態 Download PDF

Info

Publication number
JP2024518429A
JP2024518429A JP2023568486A JP2023568486A JP2024518429A JP 2024518429 A JP2024518429 A JP 2024518429A JP 2023568486 A JP2023568486 A JP 2023568486A JP 2023568486 A JP2023568486 A JP 2023568486A JP 2024518429 A JP2024518429 A JP 2024518429A
Authority
JP
Japan
Prior art keywords
compound
crystalline form
cancer
solvent
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518429A5 (https=
Inventor
ニプン ダヴァール
マシュー ジョンソン
スレシュ マンタティ
ジェマ ズンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JP2024518429A publication Critical patent/JP2024518429A/ja
Publication of JP2024518429A5 publication Critical patent/JP2024518429A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2023568486A 2021-05-11 2022-05-10 ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態 Pending JP2024518429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187125P 2021-05-11 2021-05-11
US63/187,125 2021-05-11
PCT/US2022/028606 WO2022240886A1 (en) 2021-05-11 2022-05-10 Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile

Publications (2)

Publication Number Publication Date
JP2024518429A true JP2024518429A (ja) 2024-05-01
JP2024518429A5 JP2024518429A5 (https=) 2025-05-20

Family

ID=81854861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568486A Pending JP2024518429A (ja) 2021-05-11 2022-05-10 ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態

Country Status (6)

Country Link
US (1) US20240228438A1 (https=)
EP (1) EP4337638A1 (https=)
JP (1) JP2024518429A (https=)
CN (1) CN117769540A (https=)
TW (1) TW202308991A (https=)
WO (1) WO2022240886A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542258A (ja) * 2010-11-10 2013-11-21 セラヴァンス， インコーポレーテッド アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態
WO2017006968A1 (ja) * 2015-07-07 2017-01-12 日本たばこ産業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその中間体
WO2017090756A1 (ja) * 2015-11-27 2017-06-01 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
JP2020503330A (ja) * 2016-12-28 2020-01-30 トニックス ファーマ ホールディングス リミテッド チアネプチンシュウ酸塩および多形

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021095835A1 (en) * 2019-11-13 2021-05-20 Taiho Pharmaceutical Co., Ltd. Novel salt of terphenyl compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542258A (ja) * 2010-11-10 2013-11-21 セラヴァンス， インコーポレーテッド アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態
WO2017006968A1 (ja) * 2015-07-07 2017-01-12 日本たばこ産業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその中間体
WO2017090756A1 (ja) * 2015-11-27 2017-06-01 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
JP2020503330A (ja) * 2016-12-28 2020-01-30 トニックス ファーマ ホールディングス リミテッド チアネプチンシュウ酸塩および多形

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005787958 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005787956 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005787957 *

Also Published As

Publication number Publication date
EP4337638A1 (en) 2024-03-20
CN117769540A (zh) 2024-03-26
WO2022240886A1 (en) 2022-11-17
TW202308991A (zh) 2023-03-01
US20240228438A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
TWI874490B (zh) 三苯化合物之新穎鹽類
AU2020276695A1 (en) New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
JP2024518429A (ja) ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態
JP2022068350A (ja) Ｎ－（４－（（３－（２－アミノ－４－ピリミジニル）－２－ピリジニル）オキシ）フェニル）－４－（４－メチル－２－チエニル）－１－フタラジンアミンの薬学的に許容される塩の結晶形態及びその使用
JP2025131661A (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
EP2542548A1 (en) Process for preparation of polymorphic form and new polymorphic form of imatinib mesylate isolated in that process
CN109843880B (zh) 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型
JP7618575B2 (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
HK40108981A (zh) 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式
JP7788550B2 (ja) ターフェニル化合物の安息香酸塩の製造方法
EP2345649A1 (en) Benzimidazole compound in crystal form and salt thereof
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
CN121941687A (zh) 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途
BR112021022335B1 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin4-il)-4- metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf, seus usos, e composição farmacêutica
HK40076742A (en) Novel salt of terphenyl compound
JP2020513006A (ja) アファチニブジマレアートの新規形態

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250620

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20250620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203